CD5 B cells and B-cell malignancies

Curr Opin Hematol. 1999 Jan;6(1):30-6. doi: 10.1097/00062752-199901000-00006.


Over the past year, progress has been made in understanding of the physiology and disease associations of CD5+ (B1) B cells, although their exact role in pathogenesis remains unclear. Earlier studies on the negative function of CD5 within the B-cell receptor complex have been substantiated, and it seems likely that soon the signaling pathways used by this coreceptor will be elucidated. Progress in diagnosis, physiology, and etiopathogenesis of CD5+ malignancies has been made, particularly in B-cell chronic lymphocytic leukemia. The low-level expression of surface immunoglobulin has been explained by the mutations that occur in the associated CD79b. Two new potential tumor-suppressor genes have been identified in the hot spot of chromosome 13q, which provides an exciting step forward in understanding of the etiopathogenesis of some B-cell chronic lymphocytic leukemia. Activated signal transducers for activation of transcription factors molecules have been shown to be phosphorylated on different amino acids in B1 and chronic lymphocytic leukemia tumors, although the significance of this is, as yet, unclear. Finally, aberrant expression of CD40L by chronic lymphocytic leukemia T cells may contribute to the immunodeficiency that develops in these patients.

Publication types

  • Review

MeSH terms

  • Apoptosis / physiology
  • B-Lymphocytes / immunology*
  • CD5 Antigens / blood*
  • Chronic Disease
  • Epitopes
  • Humans
  • Karyotyping
  • Leukemia, B-Cell / genetics
  • Leukemia, B-Cell / immunology*
  • Lymphoma, B-Cell / genetics
  • Lymphoma, B-Cell / immunology*


  • CD5 Antigens
  • Epitopes